Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances

Neuropsychopharmacology

Volumn 35, Issue 8, 2010, Pages 1761-1774

  Polter, Abigail ^a,b   Beurel, Eléonore ^a   Yang, Sufen ^a   Garner, Rakesha ^a   Song, Ling ^a   Miller, Courtney A ^b   Sweatt, J David ^b   McMahon, Lori ^b,c   Bartolucci, Alfred A ^d   Li, Xiaohua ^a,b   Jope, Richard S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Amphetamine; Bipolar disorder; Depression; Glycogen synthase kinase 3; Lithium

Indexed keywords

ALANINE; AMPHETAMINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; SERINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; BLOOD CELL; BRAIN; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; HUMAN CELL; HYPERACTIVITY; MALE; MOOD DISORDER; MOUSE; MUTATION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; STRESS;

ADULT; AGED; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; ELECTROSHOCK; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; FEAR; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HELPLESSNESS, LEARNED; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MICE; MICE, KNOCKOUT; MIDDLE AGED; MOOD DISORDERS; PAIN; PAIN THRESHOLD; PHOSPHORYLATION; SERINE; SWIMMING;

EID: 77953596703     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.43     Document Type: Article

References (58)

1. Bannerman DM, Grubb M, Deacon RM, Yee BK, Feldon J, Rawlins JN (2003). Ventral hippocampal lesions affect anxiety but not spatial learning. Behav Brain Res 139: 197-213.
2. Beaulieu JM, Gainetdinov RR, Caron MG (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49: 327-347.
3. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR et al (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 101: 5099-5104.
4. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC et al (2008). Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105: 1333-1338.
5. Castri P, Iacovelli L, De Blasi A, Giubilei F, Moretti A, Capone FT et al (2007). Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. Eur J Neurosci 26: 2469-2472.
6. Chen G, Huang LD, Jiang YM, Manji HK (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330.
7. Crowley JJ, Jones MD, O'Leary OF, Lucki I (2004). Automated tests for measuring the effects of antidepressants in mice. Pharmacol Biochem Behav 78: 269-274.
8. Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
9. Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29: 571-625.
10. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
11. De Sarno P, Li X, Jope RS (2002). Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164.
12. Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS (2007). A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61: 661-670.
13. Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597-606.
14. Eom TY, Jope RS (2009). Blocked inhibitory serine-phosphoryla-tion of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation. Biol Psychiatry 66: 494-502.
15. Feder A, Nestler EJ, Charney DS (2009). Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 10: 446-457.
16. Force T, Woodgett JR (2009). Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 284: 9643-9647.
17. Frame S, Cohen P, Biondi RM (2001). A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327.
18. Gladkevich A, Kauffman HF, Korf J (2004). Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28: 559-576.
19. Gold PW, Chrousos GP (2002). Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 7: 254-275.
20. Gould TD, Einat H (2007a). Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 31: 825-831.
21. Gould TD, Einat H, Bhat R, Manji HK (2004a). AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 7: 387-390.
22. Gould TD, O'Donnell KC, Picchini AM, Manji HK (2007b). Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 32: 1321-1333.
23. Gould TD, Zarate CA, Manji HK (2004b). Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry 65: 10-21.
24. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK (2006). Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 60: 93-105.
25. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90.
26. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P et al (2009). Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 66: 721-728.
27. Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberte C et al (2009). Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain 2: 35.
28. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry 55: 781-784.
29. Kalueff AV, Wheaton M, Murphy DL (2007). What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res 179: 1-18.
30. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R et al (2007). Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 61: 240-245.
31. Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459.
32. Kozlovsky N, Amar S, Belmaker RH, Agam G (2006). Psychotropic drugs affect Ser9-phosphorylated GSK-3beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol 9: 337-342.
33. Kurtuncu M, Luka LJ, Dimitrijevic N, Uz T, Manev H (2005). Reliability assessment of an automated forced swim test device using two mouse strains. J Neurosci Methods 149: 26-30.
34. LeDoux JE (2000). Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
35. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS et al (2007a). Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 61: 216-222.
36. Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA (2007b). Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 10: 7-19.
37. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS (2004). In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsy-chopharmacology 29: 1426-1431.
38. Liang MH, Chuang DM (2006). Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem 281: 30479-30484.
39. Liang MH, Chuang DM (2007). Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 282: 3904-3917.
40. Maggio N, Segal M (2009). Differential modulation of long-term depression by acute stress in the rat dorsal and ventral hippocampus. J Neurosci 29: 8633-8638.
41. Mai L, Jope RS, Li X (2002). BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 82: 75-83.
42. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104-9110.
43. Martinowich K, Schloesser RJ, Manji HK (2009). Bipolar disorder: from genes to behavior pathways. J Clin Invest 119: 726-736.
44. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R et al (2005). Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 24: 1571-1583.
45. O'Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S et al (2004). Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24: 6791-6798.
46. Phiel CJ, Klein PS (2001). Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789-813.
47. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439.
48. Pittenger C, Duman RS (2008). Stress, depression, and neuroplas-ticity: a convergence of mechanisms. Neuropsychopharmacology 33: 88-109.
49. Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I et al (2006). Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 26: 9022-9029.
50. Rosa AO, Kaster MP, Binfare RW, Morales S, Martin-Aparicio E, Navarro-Rico ML et al (2008). Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsycho-pharmacol Biol Psychiatry 32: 1549-1556.
51. Rowe MK, Wiest C, Chuang DM (2007). GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 31: 920-931.
52. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V et al (2007). Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 104: 6406-6411.
53. Scheiderer CL, Dobrunz LE, McMahon LL (2004). Novel form of long-term synaptic depression in rat hippocampus induced by activation of alpha 1 adrenergic receptors. J Neurophysiol 91: 1071-1077.
54. Stambolic V, Ruel L, Woodgett JR (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664-1668.
55. Sullivan PF, Fan C, Perou CM (2006). Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141: 261-268.
56. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, Shyu KG et al (2005). Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 133: 1-5.
57. Wang QM, Park IK, Fiol CJ, Roach PJ, DePaoli-Roach AA (1994). Isoform differences in substrate recognition by glycogen synthase kinases 3 alpha and 3 beta in the phosphorylation of phosphatase inhibitor 2. Biochemistry 33: 143-147.
58. Woodgett JR (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438.